Last reviewed · How we verify
RASi plus carvedilol
This combination reduces blood pressure and improves heart function by blocking angiotensin II signaling (RASi) while simultaneously reducing heart rate and contractility through beta-blockade (carvedilol).
This combination reduces blood pressure and improves heart function by blocking angiotensin II signaling (RASi) while simultaneously reducing heart rate and contractility through beta-blockade (carvedilol). Used for Heart failure with reduced ejection fraction, Hypertension, Post-myocardial infarction.
At a glance
| Generic name | RASi plus carvedilol |
|---|---|
| Also known as | Randomized, Double blind, Controlled, Trial |
| Sponsor | Federal University of Minas Gerais |
| Drug class | ACE inhibitor or ARB combined with non-selective beta-blocker |
| Target | Angiotensin II receptor / ACE enzyme; beta-1 and beta-2 adrenergic receptors; alpha-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
RASi (renin-angiotensin system inhibitor) blocks the formation or action of angiotensin II, a potent vasoconstrictor, thereby lowering blood pressure and reducing cardiac workload. Carvedilol is a non-selective beta-blocker with alpha-blocking properties that decreases heart rate, contractility, and peripheral vascular resistance. Together, these agents provide complementary hemodynamic benefits for heart failure and hypertension management.
Approved indications
- Heart failure with reduced ejection fraction
- Hypertension
- Post-myocardial infarction
Common side effects
- Hypotension
- Bradycardia
- Dizziness
- Fatigue
- Cough (RASi-related)
- Hyperkalemia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RASi plus carvedilol CI brief — competitive landscape report
- RASi plus carvedilol updates RSS · CI watch RSS
- Federal University of Minas Gerais portfolio CI